NDAORALCAPSULE, EXTENDED RELEASE
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
5/8 — Partial
NAMZARIC (memantine hydrochloride and donepezil hydrochloride) by AbbVie is medications: memantine hydrochloride and donepezil hydrochloride. Approved for moderate to severe dementia of the alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily. First approved in 2014.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAMZARIC is a fixed-dose combination oral capsule containing memantine hydrochloride and donepezil hydrochloride, approved for moderate to severe Alzheimer's dementia in patients stabilized on donepezil monotherapy. Memantine works as an NMDA receptor antagonist to modulate glutamate excitotoxicity, while donepezil enhances acetylcholine levels via cholinesterase inhibition. Neither agent prevents or slows neurodegeneration, but both provide symptomatic cognitive benefit.
$0.108BPart D
LOE ApproachingStable
3.1 years to LOEProduct is in peak sales phase but approaching loss of exclusivity in 3.2 years, indicating brand teams are transitioning from growth to LOE defense and lifecycle extension strategies.
Mechanism of Action
medications: memantine hydrochloride and donepezil hydrochloride. Each of those medications is postulated to have a different mechanism in Alzheimer's disease. Memantine Persistent activation of central nervous system NMDA receptors by the excitatory amino acid glutamate has been hypothesized to…
Worked on NAMZARIC at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.